Similarly, in CIMP vs. LOW PM cell lines, several CP were inhibited, including IL-17 signaling, PD-1/PD-L1 cancer immunotherapy pathway, T Cell Receptor (TCR) and BCR signaling, that exert a pivotal role in coordinating an efficient adaptive cell-mediated immune response, and non-canonical NF-κB signaling, implicated in T cell development. The gene discussed is NFKB1; the disease is cancer.